Ma A, Zhang W, Liu Z
Department of Cardiology, First Affiliated Hospital of Xi'an Medical University, China.
Blood Press Suppl. 1996;3:53-5.
We have already proved that the mitochondrial membrane-phospholipid (MMP) injury changes of peripheral lymphocytes in patients with heart failure can be used as an injury indicator of myocardia, and are related to the long-term prognosis. In the present study, MMP localization of the peripheral lymphocytes was performed by modified Demer's tricomplex flocculation method, and we compared the changes, after classification, between the pre-treatment and the 12-week post-treatment, of coenzyme Q10 (Co.Q10) and captopril in 61 hospitalized patients with dilated cardiomyopathy (DCM). They were followed up for 16.1 +/- 7.8 months (mean). The results showed that compared with the placebo, Co.Q10 and captopril could significantly protect against and repair MMP injury and improve the heart function of patients with DCM after 12 weeks, and the 2-year survival rate rose significantly by 72.7% for Co.Q10, and 64.0% for captopril, vs 24.7% for placebo. As for Longrank test, X2 equals 4.660 and 6.318, respectively, with both p < 0.05. The aforementioned results indicate that MMP injury of peripheral lymphocytes can predict the prognosis of the patients with DCM, thus the protection and repairment of MMP injury can improve the life-quality and prolong the life-span of the patients.
我们已经证明，心力衰竭患者外周淋巴细胞的线粒体膜磷脂（MMP）损伤变化可作为心肌损伤指标，并与长期预后相关。在本研究中，采用改良的德默三色复合絮凝法对外周淋巴细胞的MMP进行定位，并比较了61例住院扩张型心肌病（DCM）患者在辅酶Q10（Co.Q10）和卡托普利治疗前及治疗12周后的MMP变化。对患者进行了16.1±7.8个月（平均）的随访。结果显示，与安慰剂相比，Co.Q10和卡托普利在12周后可显著保护并修复MMP损伤，改善DCM患者的心功能，Co.Q10组的2年生存率显著提高72.7%，卡托普利组提高64.0%，而安慰剂组为24.7%。对于长秩检验，X2分别等于4.660和6.318，均p<0.05。上述结果表明，外周淋巴细胞的MMP损伤可预测DCM患者的预后，因此对MMP损伤的保护和修复可提高患者的生活质量并延长其寿命。
